How does treatment with Trelegy (fluticasone furoate, vilanterol, umeclidinium) injections for asthma affect the course of H1N1 (Influenza A) flu-associated bronchopneumonia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Being on Tezspira injections for asthma could potentially be beneficial if you develop H1N1 flu 2009 bronchopneumonia, as it may help reduce airway inflammation and prevent severe asthma flares. However, Tezspira is not a treatment for influenza or pneumonia itself. If you develop H1N1 bronchopneumonia while on Tezspira, you should continue your regular Tezspira dosing schedule (210 mg subcutaneously every 4 weeks) unless your doctor advises otherwise, but you will also need appropriate antiviral treatment like oseltamivir (Tamiflu) and possibly antibiotics if bacterial pneumonia develops, as recommended by the CDC 1. The standard treatment for H1N1 influenza with bronchopneumonia would include antiviral medication, supportive care, oxygen therapy if needed, and close monitoring of respiratory status. People with asthma are at higher risk for complications from influenza, so maintaining good asthma control with medications like Tezspira is important, but prompt medical attention for flu symptoms is essential, and treatment should not be delayed while awaiting diagnostic test results 1. Some key considerations for treatment include:

  • Early antiviral treatment can reduce the risk of complications from influenza, such as pneumonia, respiratory failure, and death 1
  • Persons with chronic pulmonary conditions, including asthma, are at higher risk for influenza complications and should receive antiviral treatment if suspected or confirmed to have influenza 1
  • Treatment decisions should be informed by knowledge of influenza activity in the community and clinical judgment regarding the patient's disease severity and progression, age, underlying medical conditions, likelihood of influenza, and time since onset of symptoms 1

From the Research

Effect of Trezspira Injections on H1N1 Flu 2009 Bronchopneumonia in Asthma Patients

  • There are no direct studies on the effect of Trezspira injections on H1N1 flu 2009 bronchopneumonia in asthma patients.
  • However, studies have shown that oseltamivir treatment can be effective in managing influenza A and B, including H1N1, in patients with asthma 2, 3, 4, 5.
  • A study found that asthma patients with H1N1 influenza infection who took oseltamivir had a higher rate of acute asthma exacerbations and pneumonia development compared to those with other upper respiratory infections 2.
  • Another study suggested that early initiation of oseltamivir treatment can provide greater clinical benefits and may be beneficial in preventing H1N1 transmission 5.
  • The use of corticosteroids, such as those found in Trezspira injections, has been shown to be effective in treating acute lung injury and multiple organ dysfunction scores in patients with H1N1 pneumonia and ARDS 6.
  • However, the specific effect of Trezspira injections on H1N1 flu 2009 bronchopneumonia in asthma patients is not well understood and requires further research.

Asthma and H1N1 Influenza Infection

  • H1N1 influenza infection can affect the clinical course of asthma, leading to more severe manifestations such as wheezing, acute asthma exacerbations, and pneumonia development 2.
  • Oseltamivir treatment has been shown to be effective in managing H1N1 influenza infection in asthma patients, but the clinical course may still be more severe than expected 2.
  • Vaccination against influenza remains the gold standard for preventing influenza in patients with asthma and/or COPD 3.

Oseltamivir Treatment

  • Oseltamivir is a selective neuraminidase enzyme inhibitor that has been shown to be effective in treating and preventing influenza A and B, including H1N1 4.
  • Early initiation of oseltamivir treatment can provide greater clinical benefits and may be beneficial in preventing H1N1 transmission 5.
  • Oseltamivir is generally well-tolerated, but nausea and vomiting are common adverse effects associated with its use 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of influenza in patients with asthma or chronic obstructive pulmonary disease.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001

Research

Oseltamivir.

Journal of postgraduate medicine, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.